Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study

OBJECTIVE-To compare the pharmacokinetics and pharmacodynamics of NPH, glargine, and detemir insulins in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS-This study used a single-blind, three-way, cross-over design. A total of 18 type 2 diabetic subjects underwent a euglycemic clamp for 32 h after a subcutaneous injection of 0.4 units/kg at 2200 h of either NPH, glargine, or detemir after 1 week of bedtime treatment with each insulin. RESULTS-The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 +/- 688; 1,081 +/- 785; and 1,170 +/- 703 mg/kg, respectively; P 150 mg/dL. CONCLUSIONS-Compared with NPH and detemir, glargine provided greater metabolic activity and superior glucose control for up to 32 h.Lucidi, P.; Porcellati, F.; Rossetti ., P.; Candeloro, P.; Cioli, P.; Marzotti, S.; Andreoli, AM.... (2011). Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care. 34(6):1312-1314. doi:10.2337/dc10-1911S1312131434